Structural Biology > Nova Content
Written by Daniel A. Kamkar and Agnes Juang, Ph.D.
On August 2, 2017, the U.S. Food and Drug Administration approved the use of Imbruvica® (ibrutinib) for the ... Read More »
Written by Robert J. Hilton and Eric Furman, Ph.D.
Before Prost, O’Malley, and Wallach. Appeal from the District of Connecticut (nonprecedential).
On... Read More »
Written by Jane Xia and Jing Liu, Ph.D.
MILLENNIUM PHARMACEUTICALS, INC. v. SANDOZ INC
(Fed. Cir. July 17, 2017) (NEWMAN, Mayer, O’Malley)
This case ... Read More »
Written by Marc Chatenay-Lapointe, Ph.D. and Jason Jardine
On July 13, 2017, the U.S. Food and Drug Administration approved Tremfya (guselkumab), a biologic... Read More »
Written by Scott Siera, Ph.D. and Michael L. Fuller
Stanford University v. The Chinese University of Hong Kong. Federal Circuit Appeal No. 2015-2011. Decided June ... Read More »
Written by Hyeongsu Rick Park and Kerry S. Taylor, Ph.D.
The Patent Trial and Appeal Board (PTAB) terminated a patent interference proceeding between the... Read More »
Written by Daniel K. Yarbrough, Ph.D. and Jing Liu, Ph.D.
Once considered parasites, free riders, or “opportunistic pathogens,” in recent years the... Read More »
Written by Robert J. Hilton, Ph.D. and Jing Liu, Ph.D.
On January 13, 2017, the Supreme Court granted certiorari in Amgen v. Sandoz, 794. f. 3d 1347 (Fed. Cir... Read More »
Written by Paul Chang, Ph.D. and Brenden Gingrich, Ph.D.
Anticipation by inherent disclosure requires that a single prior art reference necessarily includes the... Read More »
Written by Marc Chatenay-Lapointe, Ph.D. and Michael L. Fuller
On December 23, 2016, the U.S. Food and Drug Administration approved SPINRAZA™ (nusinersen)... Read More »
A unique public-private partnership provides medical research centers and the patents they generate with a more efficient and rewarding path toward... Read More »
Written by Agnes Juang, Ph.D. and Scott Siera, Ph.D.
Once a European patent application has been granted, all patentees must then choose to validate the granted... Read More »
On September 20, 2016, the U.S. Court of Appeals for the Federal Circuit issued an opinion affirming the summary judgement that Abbott’s U.S. Patent No... Read More »
Unitary patents in Europe
The European unitary patent and Unitary Patent Court (UPC) are slated to go into effect in early 2017. These monumental changes will... Read More »
On July 14, 2016, the U.S. Patent and Trademark Office issued new subject matter eligibility guidance for life science claims following a ruling by the Federal... Read More »
On July 5, 2016, the U.S. Court of Appeals for the Federal Circuit issued an opinion vacating the summary judgment of invalidity of U.S. Patent No. 7,604,929... Read More »
A new announcement last month from Monsanto Company could have tremendous impact in both agriculture and patent allocation for genetic modification of seeds for crop... Read More »
DARPA, responsible for advanced research for the DoD, recently engaged a team of Harvard-led researchers to explore the feasibility of creating “soft”... Read More »
Ever forget to take your morning pills? Or can’t remember if you have to take the blue pill today or the yellow one? Suddenly, life just got a lot... Read More »
Engineered skin and muscle produced like spools of tape might sound like science fiction, but it’s not. Researchers at the University of Toronto have developed... Read More »